NVNO

enVVeno Medical Corporation · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website envveno.com
Employees(FY) 30
ISIN US29415J1060

Performance

-7.04%

-5.37%

-39.73%

-33.54%

-38.33%

YTD

-11.7%

Profile

enVVeno Medical Corporation, a clinical med-tech company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases. The company's lead product is the VenoValve, a surgical implant being developed for the treatment of chronic venous disease. Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Advanced Technical Analysis

Technical Analysis of NVNO 2024-12-02

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. The Technical Score of 31 further reinforces the bearish outlook, indicating that the stock may face challenges in gaining upward momentum in the near term.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of NVNO

Stock Rank

Recent News & Updates

2024-11-26 19:30
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website(Accesswire)
2024-11-19 19:30
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium(Accesswire)
2024-11-18 19:15
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval(Accesswire)
2024-10-30 20:35
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year(Accesswire)
2024-10-27 20:30
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)(Accesswire)
2024-09-26 10:20
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering(Accesswire)
2024-09-26 04:05
enVVeno Medical Corporation Announces Proposed Public Offering(Accesswire)
2024-09-02 21:00
enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing(Accesswire)
2024-08-13 21:00
enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)(Accesswire)
2024-07-31 20:05
enVVeno Medical Reports Second Quarter 2024 Financial Results and Provides Corporate Update(Accesswire)
2024-06-24 21:00
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series(Accesswire)
2024-06-20 20:35
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting(Accesswire)
2024-06-17 00:00
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024(Accesswire)
2024-06-16 20:00
Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024(Accesswire)
2024-06-09 20:00
JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024(Accesswire)
2024-05-08 11:54
NVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024(Investorplace)
2024-05-08 04:15
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update(Accesswire)
2024-04-23 18:15
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium(Accesswire)
2024-04-23 18:15
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium(Accesswire)
2024-04-15 21:00
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024(Accesswire)
2024-04-08 20:45
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer(Accesswire)
2024-03-14 21:00
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity(Accesswire)
2024-03-05 19:40
Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual Meeting(Accesswire)
2024-02-29 03:15
enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update(Accesswire)
2024-02-19 19:30
Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024(Accesswire)
2023-12-13 22:30
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium(Accesswire)
2023-11-15 19:45
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium(Accesswire)
2023-10-25 20:05
enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update(Accesswire)
2023-10-17 22:00
JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023(Accesswire)
2023-10-11 21:00
enVVeno Medical to Participate at the Virtual Investor Ask the CEO Conference(Accesswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.